Clinical Trial

Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment

Study acronym: CHAPERONE-CKM
Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-04.
Trial Details
NCT Number NCT07403669
Lead Sponsor Aventyn, Inc.
Collaborators: Dignity Health, Arizona Heart Foundation, Arizona State University, University of Arizona, University of Phoenix College of Nursing, Creighton School of Medicine, Phoenix Arizona, Karolinska University Hospital, Partnership for Economic Innovation Arizona, Kanasu Labs, Intel Corporation
Conditions Acute MI, Heart Failure, Diabetes Mellitus, Kidney Disease
Enrollment 300 participants
Start Date 2025-10-22
Primary Completion 2026-10-22 (estimated)
Study Completion 2027-04-22 (estimated)
Updated on ClinicalTrials.gov 2026-02-12